Predictors of metabolic monitoring among schizophrenia patients with a new episode of second-generation | BioMed Central BMC Psychiatry Open Access Research article Predictors of metabolic monitoring among schizophrenia patients with a new episode of second-generation antipsychotic use in the Veterans Health Administration Lizheng Shi 1 2 3 Haya Ascher-Svanum4 Yi-Ju Chiang1 Yingnan Zhao1 Vivian Fonseca2 and Daniel Winstead2 Address 1School of Public Health and Tropical Medicine Tulane University 1440 Canal Street New Orleans LA 70112 USA 2School of Medicine Tulane University 1430 Tulane Avenue New Orleans LA 70112 USA 3Southeast Louisiana Veterans Health Care System 1601 Perdido Street New Orleans LA 70112 USA and 4US Outcomes Research Eli Lilly and Company Lilly Corporate Center DC 4133 Indianapolis Indiana 46285 USA Email Lizheng Shi - lshi1@ Haya Ascher-Svanum - Ascher-Svanum_Haya@ Yi-Ju Chiang - chiang_642@ Yingnan Zhao - yzhao3@ Vivian Fonseca - vfonseca@ Daniel Winstead - winstead@ Corresponding author Published 18 December 2009 Received 8 March 2009 BMC Psychiatry 2009 9 80 doi l47l-244X-9-80 Accepted 18 December 2009 This article is available from http l47l-244X 9 80 2009 Shi et al licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Background To examine the baseline metabolic monitoring MetMon for second generation antipsychotics SGA among patients with schizophrenia in the Veterans Integrated Service Network VISN 16 of the Veterans Health Administration VHA . Methods VISN16 electronic medical records for 10 2002-08 2005 were used to identify patients with schizophrenia who received a new episode of SGA treatment after 10 2003 in which the VISN 16 baseline MetMon program was implemented. Patients who underwent MetMon MetMon .
